Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis

  • Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2
     
  • Moderate-to-severe psoriasis affects more than 350,000 children worldwide3, with the physical and psychological burden disrupting important formative years4
     
  • FDA has accepted a submission for Cosentyx in moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years
     
  • Cosentyx is backed …
/by

Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness

  • Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.

  • Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.

  • Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.

…

/by